Ultragenyx Pharmaceutical Inc.

RARE trades at an RSI of 69.8 while sitting 12.72% short—a notable contradiction in market positioning. The stock hasn't reached its 52-week high, yet momentum indicators suggest overextension, creating potential friction if sellers emerge. With a $2.6B market cap and no traditional P/E valuation (likely due to unprofitability or losses), this biotech operates on clinical pipeline expectations rather than earnings fundamentals. The elevated RSI combined with meaningful short interest suggests either strong conviction among bulls despite valuation uncertainty, or a crowded long positioning vulnerable to quick reversals. The setup presents conflicting signals typical of speculative biotech plays where sentiment can shift rapidly.